Arcellx Announced The FDA Has Lifted The Partial Clinical Hold Placed On CART-ddBCMA investigational New Drug For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Arcellx announced that the FDA has lifted the partial clinical hold on its investigational new drug, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.
August 14, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's decision to lift the partial clinical hold on Arcellx's CART-ddBCMA could potentially accelerate the drug's development and approval process, potentially benefiting Arcellx in the short term.
The lifting of the FDA's partial clinical hold on Arcellx's CART-ddBCMA means that the drug can now proceed with its development and approval process. This could potentially lead to an increase in Arcellx's stock price in the short term as it signals positive progress in the company's drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100